References

Cancer statistics

10.3322/caac.21871 · 2025 · External reference

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · 2024 · External reference

Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study

2025 · External reference

Therapeutic strategies for EGFR-Mutated non-small cell lung cancer patients with osimertinib resistance

10.1186/s13045-022-01391-4 · 2022 · External reference

The effect of advances in lung-cancer treatment on population mortality

10.1056/nejmoa1916623 · 2020 · External reference

Genomic profiling of driver gene alterations in patients with non-small cell lung cancer, patterns of treatment and impact on survival outcomes: a single center experience of more than 1200 patients

10.1016/j.cllc.2025.02.001 · 2025 · External reference

Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer

10.1111/cas.16130 · 2024 · External reference

Opportunities and challenges for non-small cell lung cancer brain metastases in the immunotherapy era

10.1016/j.ctrv.2025.103014 · 2025 · External reference

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

10.1007/s00262-022-03224-2 · 2022 · External reference

Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease

10.1016/s1474-4422(24)00476-9 · 2025 · External reference

The blood-brain barrier: structure, regulation, and drug delivery

10.1038/s41392-023-01481-w · 2023 · External reference

The immune landscape in brain metastasis

10.1093/neuonc/noae219 · 2025 · External reference

Tumor immune microenvironment of brain metastases: toward unlocking antitumor immunity

10.1158/2159-8290.cd-21-0976 · 2022 · External reference

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

10.3389/fimmu.2022.964442 · 2022 · External reference

Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation

10.1038/s41467-024-48597-3 · 2024 · External reference

Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration

10.1016/j.biomaterials.2025.123730 · 2026 · External reference

Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment

10.1038/s41467-023-40579-1 · 2023 · External reference

The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications

2024 · External reference

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

10.1038/nature23643 · 2017 · External reference

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

10.1038/nature23669 · 2017 · External reference

The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1

10.1158/0008-5472.can-17-3139 · 2018 · External reference

YAP-induced PD-L1 expression drives immune evasion in BRAFi-Resistant melanoma

10.1158/2326-6066.cir-17-0320 · 2018 · External reference

Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy

10.1158/2326-6066.cir-19-0159 · 2020 · External reference

Oxygen-generating transdermal nanoplatform codelivering BRD4 proteolysis-targeting Chimera/Verteporfin/CaO(2) synergistically remodels immunosuppressive melanoma microenvironment to potentiate combination immunotherapy

10.1021/acsnano.5c04580 · 2025 · External reference

Verteporfin-mediated in situ nanovaccine based on local conventional-dose hypofractionated radiotherapy enhances antitumor and immunomodulatory effect

10.1002/advs.202413387 · 2025 · External reference

PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

10.1016/j.redox.2026.104075 · 2026 · External reference

Anti-cancer activity of verteporfin in cholangiocarcinoma

10.3390/cancers15092454 · 2023 · External reference

Engineering exosomes for targeted neurodegenerative therapy: innovations in biogenesis, drug loading, and clinical translation

10.7150/thno.117143 · 2026 · External reference

Camouflaging nanoreactor traverse the blood-brain barrier to catalyze redox Cascade for synergistic therapy of glioblastoma

10.1016/j.biomaterials.2024.122702 · 2024 · External reference

Tumor cell-derived exosomes home to their cells of origin and can be used as trojan horses to deliver cancer drugs

10.7150/thno.39434 · 2020 · External reference

Exosomes-Nature's lipid nanoparticles, a rising star in drug delivery and diagnostics

10.1021/acsnano.2c08774 · 2022 · External reference

αvβ3 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment

2024 · External reference

Nano diaminopropane tetrac and integrin alphavbeta3 expression in different cancer types: anti-Cancer efficacy and safety

2021 · External reference

Emerging therapeutic opportunities for integrin inhibitors

10.1038/s41573-021-00284-4 · 2022 · External reference

Tumour acidosis: from the passenger to the driver's seat

10.1038/nrc.2017.77 · 2017 · External reference

Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells

10.1016/j.freeradbiomed.2024.01.003 · 2024 · External reference

ROS-Induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis

10.1007/s00204-023-03476-6 · 2023 · External reference

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018

10.1038/s41418-017-0012-4 · 2018 · External reference

YAP1 contributes to NSCLC invasion and migration by promoting slug transcription via the transcription co-factor TEAD

10.1038/s41419-018-0515-z · 2018 · External reference

Fluid shear stress activates YAP to promote epithelial–mesenchymal transition in hepatocellular carcinoma

10.1002/1878-0261.13061 · 2021 · External reference

Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer

10.3390/cancers13051165 · 2021 · External reference

Autophagy in tumor immune escape and immunotherapy

10.1186/s12943-025-02277-y · 2025 · External reference

Peptide mediated in vivo tumor targeting of nanoparticles through optimization in single and multilayer in vitro cell models

10.3390/cancers10030084 · 2018 · External reference

Splenic stromal niches in homeostasis and immunity

10.1038/s41577-023-00857-x · 2023 · External reference

Cancer nanomedicine: progress, challenges and opportunities

10.1038/nrc.2016.108 · 2017 · External reference